Effects of Hochu-ekki-to and Ninjin-youei-to, traditional Japanese medicines, on porcine serum-induced liver fibrosis in rats

Immunopharmacology and Immunotoxicology

Volumn 26, Issue 2, 2004, Pages 285-298

  Ochi, Takashi ^a,b   Kawakita, Takuya ^a,b   Nomoto, Kikuo ^a,b  

^a KANEBO LTD   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Hochu ekki to; IL 13; Liver fibrosis; Ninjin youei to; Porcine serum; Sho saiko to

Indexed keywords

BU ZHONG YI QI TANG; COLLAGEN TYPE 4; HYDROXYPROLINE; INTERLEUKIN 13; PLANT EXTRACT; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; XIAO CHAI HU TANG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFECT; FEMALE; FIBROGENESIS; HERBAL MEDICINE; LIVER FIBROSIS; NONHUMAN; PRIORITY JOURNAL; RAT; REN SHEN YANG RONG TANG; TREATMENT OUTCOME;

ANIMALS; COLLAGEN TYPE IV; DRUGS, CHINESE HERBAL; FEMALE; HYDROXYPROLINE; INTERLEUKIN-13; JAPAN; LIVER CIRRHOSIS; PHYTOTHERAPY; PROCOLLAGEN-PROLINE DIOXYGENASE; RATS; RATS, WISTAR; SUS SCROFA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMALIA; PANAX GINSENG; RATTUS NORVEGICUS; SUIDAE;

EID: 2942511229     PISSN: 08923973     EISSN: None     Source Type: Journal    
DOI: 10.1081/IPH-120037726     Document Type: Article

References (43)

1. Murawaki, Y.; Nishimura, Y.; Ikuta, Y.; Idobe, Y.; Kitamura, Y.; Kawasaki, H. Plasma transforming growth factor-beta 1 concentrations in patients with chronic viral hepatitis. J. Gastroenterol. Hepatol. 1998, 13 (7), 680-684.
2. Santos, R.M.; Norton, P.; Degli, E.S.; Zern, M.A. TGF-beta isoforms in alcoholic liver disease. J. Gastroenterol. 1998, 33 (3), 383-389.
3. Remoue, F.; To, V.D.; Schacht, A.M.; Picquet, M.; Garraud, O.; Vercruysse, J.; Ly, A.; Capron, A.; Riveau, G. Gender-dependent specific immune response during chronic human Schistosomiasis haematobia. Clin. Exp. Immunol. 2001, 124 (1), 62-68.
4. Bhunchet, E.; Eishi, Y.; Wake, K. Contribution of immune response to the hepatic fibrosis induced by porcine serum. Hepatology 1996, 23 (4), 811-817.
5. Sun, M.A.; Wang, B.E.; Annoni, G.; Degli, E.S.; Biempica, L.; Zern, M.A. Two rat models of hepatic fibrosis. A morphologic and molecular comparison. Lab. Invest. 1990, 63 (4), 467-475.
6. Chiaramonte, M.G.; Donaldson, D.D.; Cheever, A.W.; Wynn, T.A. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J. Clin. Invest. 1999, 104 (6), 777-785.
7. Fallon, P.G.; Richardson, E.J.; McKenzie, G.J.; McKenzie, A.N. Schistosome infection of transgenic mice defines distinct and contrasting pathogenic roles for IL-4 and IL-13: IL-13 is a profibrotic agent. J. Immunol. 2000, 164 (5), 2585-2591.
8. Akaiwa, M.; Yu, B.; Umeshita-Suyama, R.; Terada, N.; Suto, H.; Koga, T.; Arima, K.; Matsushita, S.; Saito, H.; Ogawa, H.; Furue, M.; Hamasaki, N.; Ohshima, K.; Izuhara, K. Localization of human interleukin 13 receptor in non-haematopoietic cells. Cytokine 2001, 21 (2), 75-84.
9. Lutz, R.A.; Feng, N.; Moser, R. Binding of interleukin-13 and interleukin-4 to the interleukin (IL)-4/IL-13 receptor of human synovial fibroblasts. J. Recept. Signal Transduct. Res. 1999, 19 (1-4), 181-190.
10. Doucet, C.; Brouty-Boye, D.; Pottin-Clemenceau, C.; Jasmin, C.; Canonica, G.W.; Azzarone, B. IL-4 and IL-13 specifically increase adhesion molecule and inflammatory cytokine expression in human lung fibroblast. Int. Immunol. 1998, 10 (10), 1421-1433.
11. de Vries, J.E. Molecular and biological characteristics of interleukin-13. Chem. Immunol. 1996, 63, 204-218.
12. Yamaoka, Y.; Kawakita, T.; Nomoto, K. Protective effect of a traditional Japanese medicine Hochu-ekki-to (Chinese name: Bu-zhong-yi-qi-tang), on the susceptibility against Listeria monocytogenes in infant mice. Int. Immunopharmacol. 2001, 1 (9-10), 1669-1677.
13. Yamaoka, Y.; Kawakita, T.; Nomoto, K. Protective effect of a traditional Japanese medicine, Bu-zhong-yi-qi-tang (Japanese name: Hochu-ekki-to), on the resistant stress-induced susceptibility against Listeria monocytogenes. Immunopharmacology 2000, 48 (1), 34-42.
14. Yamaoka, Y.; Kawakita, T.; Kishihara, K.; Nomoto, K. Effect of a traditional Chinese medicine Bu-zhong-yi-qi-tang on the protection against an oral infection with Listeria monocytogenes. Immunopharmacology 1998, 39 (3), 215-223.
15. Ishimitsu, R.; Nishimura, H.; Kawauchi, H.; Kawakita, T.; Yoshikai, Y. Dichotomous effects of a traditional Japanese medicine, Bu-zhong-yi-qi-tang on allergic asthma in mice. Int. Immunopharmacol. 2001, 1 (5), 857-865.
16. Kaneko, M.; Kishihara, K.; Kawakita, T.; Nakamura, T.; Takimoto, H.; Nomoto, K. Suppression of IgE production in mice treated with a traditional Chinese medicine, Bu-zhong-yi-qi-tang (Japanese name: Hochu-ekki-to). Immunopharmacology 1997, 36 (1), 79-85.
17. Kaneko, M.; Kawakita, T.; Nomoto, K. Inhibition of eosinophil infiltration into the mouse peritoneal cavity by a traditional Chinese medicine, Bu-zhong-yi-qi-tang (Japanese name: Hochu-ekki-to). Immunopharmacol. Immunotoxicol. 1999, 21 (1), 125-140.
18. Harigai, E.; Nakai, S.; Kawakita, T.; Nomoto, K. Combined treatment with Ren-shen-yang-rong-tang (Japanese name: Nijin-youei-to) plus prednisolone on adjuvant-induced arthritis in Lewis rat. Int. J. Immunopharmacol. 1995, 17 (5), 411-418.
19. Nakai, S.; Kawakita, T.; Himeno, K.; Nomoto, K. Combined treatments with Ninjin-youei-to (Ren-shen-yang-rong-tang) plus a suboptimal dose of prednisolone on autoimmune nephritis in MRL/lpr mice. Int. Immunopharmacol. 1998, 20 (6), 275-284.
20. Nakai, S.; Kawakita, T.; Nagasawa, H.; Himeno, K.; Nomoto, K. Thymus-dependent effects of a traditional Chinese medicine, Ren-shen-yang-rong-tang (Japanese name: Ninjin-youei-to), in autoimmune MRL/MP-lpr/lpr mice. Int. J. Immunopharmacol. 1996, 18 (4), 271-279.
21. Zhou, N.N.; Nakai, S.; Kawakita, T.; Oka, M.; Nagasawa, H.; Himeno, K.; Nomoto, K. Combined treatment of autoimmune MRL/MP-lpr/lpr mice with a herbal medicine, Ren-shen-yang-rong-tang (Japanese name: Ninjin-youei-to) plus suboptimal dosage of prednisolone. Int. J. Immunopharmacol. 1994, 16 (10), 845-854.
22. Nakai, S.; Kawakita, T.; Zhou, N.N.; Matsuura, K.; Oka, M.; Nagasawa, H. ; Saito, Y.; Suzuki, A.; Himeno, K.; Nomoto, K. Treatment effect of a traditional Chinese medicine, Ren-shen-yang-rong-tang (Japanese name: Ninjin-youei-to), on autoimmune MRL/MP-lpr/lpr mice. Int. J. Immunopharmacol. 1993, 15 (5), 589-596.
23. Matsuta, M.; Kosaka, N.; Nakatsuji, S.; Awata, N. The inhibitory effects of Sho-saiko-to on porcine serum-induced hepatic fibrosis in rats. J. Tradit. Med. 1998, 15 (2), 135-140.
24. Matsumoto, E.; Muragaki, Y.; Ooshima, A. Increased serum type IV collagen peptide in carbon tetrachloride-treated rats. Acta Pathol. Jpn. 1989, 39 (1), 23-29.
25. Matsumoto, Y.; Sakaida, I.; Uchida, K. Prolyl 4-hydroxylase inhibitor (HOE 077) inhibits pig serum-induced rat liver fibrosis by preventing stellate cell activation. J. Hepatol. 1997, 27 (1), 185-192.
26. Kauschke, S.G.; Knorr, A.; Heke, M.; Kohlmeyer, J.; Schauer, M.; Theiss, G.; Waehler, R.; Burchardt, E.R. Two assays for measuring fibrosis: reverse transcriptase-polymerase chain reaction of collagen alpha(1) (III) mRNA is an early predictor of subsequent collagen deposition while a novel serum N-terminal procollagen (III) propeptide assay reflects manifest fibrosis in carbon tetrachloride-treated rats. Anal. Biochem. 1999, 15 (2), 131-140.
27. Amagaya, S.; Hayakawa, M.; Ogihara, Y.; Fujiwara, K. Effects of Sho-saiko-to and Dai-saiko-to on experimental hepatic fibrosis in rats. J. Tradit. Med. 1988, 5 (2), 137-145.
28. Kato, M.; Liu, W.; Yi, H.; Asai, N.; Hayakawa, A.; Kozaki, K.; Takahashi, M.; Nakashima, I. The herbal medicine Sho-saiko-to inhibits growth and metastasis of malignant melanoma primarily developed in ret-transgenic mice. J. Invest. Dermatol. 1998, 111 (4), 640-644.
29. Nelson, D.R.; Gonzalez-Peralta, R.P.; Qian, K.; Xu, Y.; Marousis, C.G.; Davis, G.L.; Lau, J.Y. Transforming growth factor-beta 1 in chronic hepatitis C. J. Viral Hepatitis 1997, 4 (1), 29-35.
30. Goumenos, D.S.; Tsamandas, A.C.; Oldroyd, S.; Sotsiou, F.; Tsakas, S.; Petropoulou, C.; Bonikos, D.; El Nahas, A.M.; Vlachojannis, J.G. Transforming growth factor-beta(1) and myofibroblasts: a potential pathway towards renal scarring in human glomerular disease. Nephron 2001, 87 (3), 240-248.
31. Oriente, A.; Fedarko, N.S.; Pacocha, S.E.; Huang, S.K.; Lichtenstein, L.M.; Essayan, D.M. Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J. Pharmacol. Exp. Ther. 1999, 292 (3), 988-994.
32. Sakaida, I.; Uchida, K.; Matsumura, Y.; Okita, K. Interferon gamma treatment prevents procollagen gene expression without affecting transforming growth factor-β1 expression in pig serum-induced rat liver fibrosis in vivo. J. Hepatol. 1998, 28 (3), 471-479.
33. Okuno, M.; Moriwaki, H.; Imai, S.; Muto, Y.; Kawada, N.; Suzuki, Y.; Kojima, S. Retinoids exacerbate rat liver fibrosis by inducing the activation of latent TGF-beta in liver stellate cells. Hepatology 1997, 26 (4), 913-921.
34. Ono, M.; Miyamura, M.; Kyotani, S.; Saibara, T.; Ohnishi, S.; Nishioka, Y. Effects of Sho-saiko-to extract on HGF and TGF-β levels of intraorgans in liver-injured rats after partial hepatectomy. J. Pharm. Pharmacol. 2000, 52 (1), 111-118.
35. Thompson, K.; Maltby, J.; Fallowfield, J.; McAulay, M.; Millward-Sadler, H.; Sheron, N. Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis. Hepatology 1998, 28 (6), 1597-1606.
36. Berg, P.A.; Klein, R.; Rocken, M. Cytokines in primary biliary cirrhosis. Semin. Liver Dis. 1997, 17 (2), 115-123.
37. Nagano, T.; Yamamoto, K.; Matsumoto, S.; Okamoto, R.; Tagashira, M.; Ibuki, N.; Matsumura, S.; Yabushita, K.; Okano, N.; Tsuji, T. Cytokine profile in the liver of primary biliary cirrhosis. J. Clin. Immunol. 1999, 19 (6), 422-427.
38. Harada, K.; Van de, W.J.; Leung, P.S.; Coppel, R.L.; Ansari, A.; Nakanuma, Y.; Gershwin, M.E. In situ nucleic acid hybridization of cytokines in primary biliary cirrhosis: predominance of the Th1 subset. Hepatology 1997, 25 (4), 791-796.
39. Sekiya, H.; Komatsu, T.; Isono, E.; Furukawa, M.; Matsushima, S.; Yamaguchi, N.; Yamauchi, K.; Hayashi, N. Decrease in the prevalence of IL-4-producing CD4+ T cells in patients with advanced stage of primary biliary cirrhosis. Am. J. Gastroenterol. 1999, 94 (12), 3589-3594.
40. Fan, X.G.; Liu, W.E.; Li, C.Z.; Wang, Z.C.; Luo, L.X.; Tan, D.M.; Hu, G.L.; Zhang, Z. Circulating Th1 and Th2 cytokines in patients with hepatitis C virus infection. Mediat. Inflamm. 1998, 7 (4), 295-297.
41. Reiser, M.; Marousis, C.G.; Nelson, D.R.; Lauer, G.; Gonzalez-Peralta, R.P.; Davis, G.L.; Lau, J.Y. Serum interleukin 4 and interleukin 10 levels in patients with chronic hepatitis C virus infection. J. Hepatol. 1997, 26 (3), 471-478.
42. Lapinski, T.W. The levels of IL-1beta; IL-4 and IL-6 in the serum and the liver tissue of chronic HCV-infected patients. Arch. Immunol. Ther. Exp. 2001, 49 (4), 311-316.
43. Gonzalez-Quintela, A.; Vidal, C.; Lojo, S.; Perez, L.F.; Otero-Anton, E. ; Gude, F.; Barrio, E. Serum cytokines and increased total serum IgE in alcoholics. Ann. Allergy, Asthma, & Immun. 1999, 83 (1), 61-67.